COVID-19 Vaccine–Associated Takotsubo Cardiomyopathy

Jani, Chinmay; Leavitt, Jeffrey I.; Omari, Omar Al; Dimaso, Alana; Pond, Kyle K.; Gannon, Stephen; Chandran, Arun; Dennis, Christopher; Colgrove, Robert C.

doi:10.1097/mjt.0000000000001379

Cited by 27 publications

(43 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The underlying mechanisms for the onset of takotsubo cardiomyopathy after the vaccination remain unclear. Jani et al described a previous case of takotsubo cardiomyopathy after the influenza vaccination and speculated that a similar mechanism related to a sympathovagal imbalance secondary to the vaccine may lead to the development of takotsubo cardiomyopathy after the COVID-19 vaccination [ 7 ]. This hypothesis may be applicable to the present case.…”

Section: Discussionmentioning

confidence: 99%

Takotsubo cardiomyopathy after vaccination for coronavirus disease 2019 in a patient on maintenance hemodialysis

Toida¹,

Uezono²,

Komatsu

et al. 2021

CEN Case Rep

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Takotsubo cardiomyopathy after vaccination for coronavirus disease 2019 in a patient on maintenance hemodialysis

Toida¹,

Uezono²,

Komatsu

et al. 2021

CEN Case Rep

View full text Add to dashboard Cite

“…There are two published reports of Takotsubo cardiomyopathy following vaccination with the Moderna [ 52 ] and AstraZeneca [ 53 ] vaccines. In both cases, other possible diagnoses were ruled out by further workups, such as angiography.…”

Section: Cardiovascular Complications Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview

et al. 2021

View full text Add to dashboard Cite

“…Vaccination is not classically associated with takotsubo cardiomyopathy. Three previous case reports exist, one recently reported case associated with the mRNA-1273 or Moderna SARS-CoV-2 vaccine, 4 and two in which influenza vaccination triggered this syndrome. 5 6 As such, the mechanism by which the ChAdOx1 nCov-19 vaccine in our patient may have resulted in transient myocardial stunning is unknown.…”

Section: Case Reportmentioning

confidence: 99%

Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination

et al. 2021

View full text Add to dashboard Cite

The global COVID-19 pandemic remains challenging with efforts for community vaccination the primary strategy to control transmission and disease sequalae in the mid to long term. While several candidate vaccines have been approved for use, there is an ongoing discussion regarding potential vaccine-related adverse events. Notably, thrombotic thrombocytopaenia has been reported following ChAdOx1 nCov-19 (AstraZeneca) vaccination. We report the first known case of takotsubo (stress) cardiomyopathy 4 days after administration of the ChAdOx1 nCoV-19 vaccine in a 72-year-old man. While this condition remains one primarily seen in females, our case represents a new trigger that warrants careful consideration when assessing patients presenting with acute coronary syndromes following ChAdOx1 nCoV-19 vaccination.

show abstract

COVID-19 Vaccine–Associated Takotsubo Cardiomyopathy

Abstract: Supplemental Digital Content is Available in the Text.

Cited by 27 publications

References 9 publications

Takotsubo cardiomyopathy after vaccination for coronavirus disease 2019 in a patient on maintenance hemodialysis

Takotsubo cardiomyopathy after vaccination for coronavirus disease 2019 in a patient on maintenance hemodialysis

Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview

Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination

Contact Info

Product

Resources

About